Real‑World Application of Autologous Hematopoietic Stem Cell Transplantation in 507 Patients With Multiple Sclerosis

Relapse free survival (RFS) at 5 years for RRMS and SPMS was 80.1% and 98.1%, respectively, while progression free survival (PFS) at 4 years for RRMS and SPMS was 95% versus 66%, respectively. For patients with RRMS, the EDSS signifcantly improved (p<0.0001) at each follow-up from a pre-HSCT mean of 3.87 to 2.51, 2.50, 2.41, 2.33, and 2.19 at 1, 2, 3, 4, and 5 years, respectively. For SPMS, the EDSS improved signifcantly only at 1 year but not thereafter. For SPMS, the mean baseline EDSS of 5.09 changed postHSCT to 4.85 (p=0.04), 4.88 (p=0.2), 4.92 (p=.27), 4.72 (p=0.07), and 4.2 (p=0.21) at 1, 2, 3, 4, 5 years, respectively...

Read More

The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP

Given the long-term treatment-free remission and better outcome measurements, autologous HSCT is more cost effective than long-term IVIG treatment in patients with chronic CIDP. However, costs will depend on patient selection, the HSCT regimen, and regional variations. Further analysis of the health economics, i.e., cost/outcome ratio, of HSCT as therapy for chronically IVIG dependent CIDP is warranted…

Read More

Autologous haematopoietic stem cell transplantation as a first-line disease- modifying therapy in patients with ‘aggressive’ multiple sclerosis

Autologous haematopoietic stem cell transplantation (AHSCT) is an effective treatment for patients with multiple sclerosis (MS) who have highly active disease, despite the use of standard disease-modifying therapies (DMTs) … AHSCT is safe and effective as a first-line DMT in inducing rapid and sustained remission in patients with ‘aggressive’ MS.

Read More